Levels of Neurofilament Light at the Preataxic and Ataxic Stages of Spinocerebellar Ataxia Type 1
Abstract
Background and Objectives
Methods
Results
Discussion
Trial Registration Information
Classification of Evidence
Get full access to this article
View all available purchase options and get full access to this article.
References
Information & Authors
Information
Published In
Copyright
Publication History
Disclosure
Study Funding
Authors
Metrics & Citations
Metrics
Citation information is sourced from Crossref Cited-by service.
Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
- Longitudinal Changes of Clinical, Imaging, and Fluid Biomarkers in Preataxic and Early Ataxic Spinocerebellar Ataxia Type 2 and 7 Carriers, Neurology, 103, 5, (2024)./doi/10.1212/WNL.0000000000209749
- Plasma neurofilament light as a promising biomarker in neuronal intranuclear inclusion disease, Journal of Neurology, 271, 4, (2042-2052), (2024).https://doi.org/10.1007/s00415-023-12160-9
- Multimodal, Longitudinal Profiling of SCA1 Identifies Predictors of Disease Severity and Progression , Annals of Neurology, 96, 4, (774-787), (2024).https://doi.org/10.1002/ana.27032
- ATXN7 -Related Cone-Rod Dystrophy , JAMA Ophthalmology, 142, 4, (301), (2024).https://doi.org/10.1001/jamaophthalmol.2024.0001
- Therapeutic Strategies for Spinocerebellar Ataxia Type 1, Biomolecules, 13, 5, (788), (2023).https://doi.org/10.3390/biom13050788
- Blood levels of neurofilament light are associated with disease progression in a mouse model of spinocerebellar ataxia type 3, Disease Models & Mechanisms, 16, 9, (2023).https://doi.org/10.1242/dmm.050144
- Baseline Clinical and Blood Biomarkers in Patients With Preataxic and Early-Stage Disease Spinocerebellar Ataxia 1 and 3, Neurology, 100, 17, (e1836-e1848), (2023)./doi/10.1212/WNL.0000000000207088
- GAA- FGF14 ataxia (SCA27B): phenotypic profile, natural history progression and 4-aminopyridine treatment response , Brain, 146, 10, (4144-4157), (2023).https://doi.org/10.1093/brain/awad157
- Systematic assessment of plasma biomarkers in spinocerebellar ataxia, Neurobiology of Disease, 181, (106112), (2023).https://doi.org/10.1016/j.nbd.2023.106112
- Autosomal dominant cerebellar ataxias: new genes and progress towards treatments, The Lancet Neurology, 22, 8, (735-749), (2023).https://doi.org/10.1016/S1474-4422(23)00068-6
- See more
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.
If you need immediate support or to place an order, please call or email customer service:
- 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
- 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
- [email protected]
We appreciate your patience during this time and apologize for any inconvenience.